The role of the NLRP3 inflammasome in pulmonary diseases.
- Published in:
- Therapeutic Advances in Respiratory Disease, 2015, v. 9, n. 4, p. 188, doi. 10.1177/1753465815586335
- By:
- Publication type:
- Article
Works matching IS 17534658 AND DT 2015 AND VI 9 AND IP 4
Results: 6
1
2
Experience with erlotinib in the treatment of non-small cell lung cancer.
- Published in:
- Therapeutic Advances in Respiratory Disease, 2015, v. 9, n. 4, p. 146, doi. 10.1177/1753465815588053
- By:
- Publication type:
- Article
3
Emerging therapies for the prevention of acute respiratory distress syndrome.
- Published in:
- Therapeutic Advances in Respiratory Disease, 2015, v. 9, n. 4, p. 173, doi. 10.1177/1753465815585716
- By:
- Publication type:
- Article
4
Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
- Published in:
- Therapeutic Advances in Respiratory Disease, 2015, v. 9, n. 4, p. 135, doi. 10.1177/1753465815581279
- By:
- Publication type:
- Article
5
Cystic fibrosis transmembrane conductance regulator biomarkers in ‘real life’: can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy?
- Published in:
- Therapeutic Advances in Respiratory Disease, 2015, v. 9, n. 4, p. 198, doi. 10.1177/1753465815579364
- By:
- Publication type:
- Article
6
Nintedanib in non-small cell lung cancer: from preclinical to approval.
- Published in:
- Therapeutic Advances in Respiratory Disease, 2015, v. 9, n. 4, p. 164, doi. 10.1177/1753465815579608
- By:
- Publication type:
- Article